This report describes 46 studies related to the use of Fructus Ponciri Seu Aurantii main blended prescriptions from Dongeuibogam. The following conclusions were reached through investigations on the prescriptions that use Fructus Ponciri Seu Aurantii as a key ingredient. 1. 19.6% of feces recorded the largest number of clinical frequency of the prescriptions in therapeutic use when Fructus Ponciri Seu Aurantii was taken as a monarch drug in prescriptions. In addition, 13.0% of each of a cough and an abdominal mass with distention and pain ranked second. 2. Prescriptions that utilize Fructus Ponciri Seu Aurantii as the main ingredient are used in the treatmeant of 5 diseases related to each of feces and an abdominal mass with distention and pain, and they are also used for treating different types of diseases related to the following ; a cough, a chest, ribs, eyes, the fullness in the chest, Qi, skin areas. 3. In the view of the causative agent of a disease, the prescriptions which are compounded with Fructus Ponciri Seu Aurantii as a monarch drug are related to endogenous agents such as seven emotion, food, deficiency, exogenous agents such as wind-cold pathogen, heat and non-endo-exopathogcnic factors like diseases due to external factors, poison. And in the view of the pathology of a disease, they are applied to the viscera pathology related to the lung, the spleen and stomach, the pathology of Qi and blood related to the reversed flow of Qi, the congestion of Qi, the deficiency of blood, the obstruction of Qi and blood, and the pathology about the retention of phlegm and fluid related to phlegm stagnation. 4. The dosage of Fructus Ponciri Seu Aurantii is 1.25pun(about 0,47g) to 2jeon(about 7.5g), however 1jeon(about 3.75g) has been taken the most for clinical application. 5. We can find out that according to herbs or prescriptions blended with itself, Fructus Ponciri Seu Aurantii makes a variety of functions to penetrate and remove stagnation, regulate Qi flow, relieve stagnation, expell wind and get rid of pain.